
    
      This is a randomized, placebo-controlled bioequivalent study with a clinical endpoint in the
      treatment of travelers' diarrhea. After 3 unformed stools are recorded within the 24 hours
      immediately preceding randomization, participants are to be randomized to receive the generic
      rifaximin 200 mg oral tablet, Xifaxan (the reference listed drug)200 mg oral tablet, or
      placebo 3 times daily for 3 days (that is; on Days 1, 2, and 3).
    
  